Industry Daily Summary
Industry Daily Summary: What Happened on October 10, 2026
Prime Medicine doses first participant in Wilson disease trial
Cell and gene therapy executives discussed manufacturing scale, while Cellares estimated the loss of a contract could push commercial production back about a year.
Today in brief
Prime Medicine gave PM577a to the first participant in a Phase I/II trial for Wilson disease caused by the H1069Q mutation.1 At a cell and gene therapy meeting, executives discussed commercial manufacturing, and Cellares estimated that losing its Bristol Myers Squibb agreement could delay production by about a year.1
Prime starts its Wilson disease trial
The first participant has received PM577a in Prime Medicine's global Phase I/II study for Wilson disease with the H1069Q mutation.1 Allen Reine expects clinical results in 2027 from the company's liver programs for Wilson disease and alpha-1 antitrypsin deficiency.1
Cell and gene therapy companies weigh manufacturing scale
Executives at the 2026 Cell and Gene Meeting on the Mesa discussed ways to make cell and gene therapies at commercial scale.1 Bristol Myers Squibb ended its manufacturing agreement with Cellares in August 2026, saying Cellares had not met commercial production requirements for Breyanzi.1 Signed in April 2024, the agreement had a stated value of up to $380 million.1 Cellares executive Fabian Gerlinghaus estimated the loss would set back commercial manufacturing by about a year.1 Gerlinghaus said Cellares had more than doubled its customer base since the start of 2026 and aims to build a portfolio of 30 to 40 active programs using autologous cells modified outside the body.1 Cellares was among eight companies selected for the FDA PreCheck program.1
Also worth knowing
-
Skylark Bio's Jodi Cook said reusing platform elements shortened development of its second indication to about 18 months, down from three and a half years for its first.1
-
Japan's PMDA accepted Nanoscope Therapeutics' MOGENRY for priority review in inherited retinal dystrophies, supported by data in retinitis pigmentosa and Stargardt disease.1